Michael Kauffman joins Karyopharm as CEO
This article was originally published in Scrip
Executive Summary
Karyopharm Therapeutics, a privately held US oncology company focused on the development of modulators of nuclear transport as therapies for cancer, inflammatory and other diseases, has named Dr Michael Kauffman chief executive officer. He was previously chief medical officer of Onyx Pharmaceuticals, which acquired Proteolix, where he lead the development of carfilzomib, a proteasome inhibitor.